The association between trace amine-associated receptor 1 (TAAR1) genetic mutations and neuropsychiatric disorders

Trace amine-associated receptor 1 (TAAR1) is an emerging drug target for the treatment of neuropsychiatric conditions. Several TAAR1-targeted therapeutics are currently in clinical and preclinical development. Emerging studies highlight links between TAAR1 single-nucleotide variants/polymorphisms and neuropsychiatric disorders. An improved understanding of TAAR1 genetic variants and their functional impact will inform the potential role of the TAAR1 system in the pathophysiology of neuropsychiatric conditions and for better therapeutic dosing. This viewpoint examines clinical and molecular studies involving TAAR1 genetic variants and their association with neuropsychiatric disorders.